Flatiron Health

The Flatiron Health company collects clinical these oncological patients  — for example, about  what medicine they took, and  about  reaction to  them. This information supplements clinical trials with data on  how different medicines work in  the real world.

2018: Roche buys Flatiron for $1.9 billion

In the middle of February, 2018 the pharmaceutical giant Roche Holding announced purchase of Flatiron Health for $1.9 billion to accelerate developments of drugs for treatment of oncological diseases.

To this transaction of Roche owned 12.6% of shares of Flatiron which were taken for $175 million. It is going to purchase the remained securities until the end of the first half of 2018. At this Flatiron will still work as the independent company.

Roche purchased software developer for the analysis of oncological data for $2 billion

As the chief executive of Roche Pharmaceuticals   Daniel O'Day noted, total absorption of Flatiron is an important step for further development of the direction of "the personalized medicines".

Roche reported that algorithms Flatiron not only will improve researches and clinical trials of corporation, but also will strengthen positions of Roche in negotiations on the prices with clients as the transaction will allow to bring new expensive methods of treatment to the market.

It gives us the best idea of the potential of our products and also creates flexibility in how we can sign new profitable contracts in the future — the head concerning pricing of Roche Jens Gruger (Jens Grueger) in an interview to Reuters agency reported.[1]

2016: Assessment in $1.2 billion

In 2016 investors estimated Flatiron at $1.2 billion.

2014: Investments of Google

In 2014 Flatiron attracted $130 million investments within a financing round which was headed by Google. At that time developers of medical technologies for work with the attractive purposes given to steel for venture investors.

Notes